// App-Quantinova.ai

: Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): 29-month (mo) follow-up from CheckMate 648.

Researchers

Presenter

  • Ken Kato

Principal Investigators

  • Yuichiro Doki

  • Jianming Xu

  • Lucjan Wyrwicz

  • Satoru Motoyama

  • Takashi Ogata

  • Hisato Kawakami

  • Chih-Hung Hsu

  • Antoine Adenis

  • Farid El Hajbi

  • Maria Di Bartolomeo

  • Maria Ignez Freitas Melro Braghiroli

  • Eva Holtved

  • Mariela A. Blum Murphy

  • Apurva Patel

  • Nan Hu

  • Yasuhiro Matsumura

  • Ian Chau

  • Yuko Kitagawa

Medical Centers

  • National Cancer Center Hospital, Tokyo, Japan

  • Ono Pharmaceutical, Osaka, Japan.

  • The Jikei University School of Medicine, Tokyo, Japan

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Royal Marsden Hospital, Surrey, United Kingdom

  • Kanagawa Cancer Center, Yokohama, Japan

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Osaka University Graduate School of Medicine, Suita, Japan

  • Kinki University Faculty of Medicine, Osaka, Japan

  • Centre Oscar Lambret, Lille, France

  • Odense University Hospital, Odense, Denmark

  • National Taiwan University Hospital, Taipei City, Taiwan

  • Klinika Onkologii i Radioterapii, Narodowy Instytut Onkologii, Warsaw, Poland

  • Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China

  • Institut du Cancer de Montpellier, Montpellier, France

  • Institute of Cancer of São Paolo, University of São Paolo, São Paolo, Brazil

  • Japanese Red Cross Okayama Hospital, Okayama, Japan

Locations

  • United Kingdom

  • Brazil

  • United States

  • Poland

  • Italy

  • China

  • Taiwan

  • Denmark

  • Japan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Esophageal squamous carcinoma cell

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Fluorouracil

  • Adrucil injection

  • Ipilimumab

  • Cisplatin

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • NCT03143153

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved